New demands of the United States under the Free Trade Agreement: pharmaceutical patents
This article is focused on the intellectual property disciplines demanded by the US to Ecuador in the process of negotiating the US-Andean Free Trade Agreement. These demands go further than Andean intellectual property norms, which are actually very favorable to the pharmaceutical corporations. Bas...
| Autor: | |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2016 |
| País: | Ecuador |
| Institución: | Universidad Andina Simón Bolivar |
| Repositorio: | Revista Comentario Internacional |
| Idioma: | español |
| OAI Identifier: | oai:revistas.uasb.edu.ec:article/156 |
| Acceso en línea: | https://revistas.uasb.edu.ec/index.php/comentario/article/view/156 |
| Access Level: | acceso abierto |
| Palabra clave: | Transnacionales propiedad intelectual patentes farmacéuticas conocimientos. Transnational corporations intellectual property patents pharmaceuticals knowledge |
| Sumario: | This article is focused on the intellectual property disciplines demanded by the US to Ecuador in the process of negotiating the US-Andean Free Trade Agreement. These demands go further than Andean intellectual property norms, which are actually very favorable to the pharmaceutical corporations. Basically the US requests are related to the protection of exclusivity rights applied to non-divulgated information; conditions for obligatory licenses; enhancing time protections to patents and second uses; and elimination of constraints to patentability. It is concluded that the intellectual property debate is essentially a political issue, although it appears as a technical matter. |
|---|